Background: Breast carcinoma is the most common malignant disease in the female population and one of the leading causes of death among women worldwide. One crucial hallmark of cancer is chronic inflammation where the immunosuppressive environment is dominant. The immunosuppressive environment is largely achieved by the interaction of tumor cells and infiltrating leukocytes. Summary: Usually, human macrophages and natural killer cells are involved in antitumor immunity. The therapeutic potential of this population against cancers has stimulated their study and led to the discovery of several different tumor-associated macrophages and natural killer cell subsets, each of which is endowed with different immunoregulatory functions. Both heterogeneity and plasticity of the tumor-associated macrophages and natural killer cell compartment, which are both tightly linked to the tumor microenvironment of different breast cancer types. Key Messages: The identification of specific tumor-associated macrophages and natural killer cell subsets endowed with particular functional capabilities might help monitor tumor-mediated responses in breast cancer patients. Currently, one of the most used strategies for breast cancer of newly diagnosed patients is neoadjuvant chemotherapy.

1.
Strehl
JD
,
Wachter
DL
,
Fasching
PA
,
Beckmann
MW
,
Hartmann
A
.
Invasive breast cancer. Recognition of molecular subtypes
.
Breast Care (Basel)
.
2011
;
6
(
4
):
258
64
.
[PubMed]
1661-3791
2.
Ellis
MJ
.
Mutational analysis of breast cancer: guiding personalized treatments
.
Breast
.
2013
Aug
;
22
Suppl 2
:
S19
21
.
[PubMed]
0960-9776
3.
Mohamed
A
,
Krajewski
K
,
Cakar
B
,
Ma
CX
.
Targeted therapy for breast cancer
.
Am J Pathol
.
2013
Oct
;
183
(
4
):
1096
112
.
[PubMed]
0002-9440
4.
Garraway
LA
,
Verweij
J
,
Ballman
KV
.
Precision oncology: an overview
.
J Clin Oncol
.
2013
May
;
31
(
15
):
1803
5
.
[PubMed]
0732-183X
5.
Ignatiadis
M
,
Sotiriou
C
.
Luminal breast cancer: from biology to treatment
.
Nat Rev Clin Oncol
.
2013
Sep
;
10
(
9
):
494
506
.
[PubMed]
1759-4774
6.
Dedic Plavetić
N
,
Kulic A Vrbanec
D
.
Role of HER-2 signalling pathway in breast cancer: biology, detection and therapeutical implications
.
Period Biol
.
2012
;
114
:
505
10
.0031-5362
7.
Radolović
P
,
Grebić
D
,
Mustać
E
,
Sebaher
I
,
Mamić
J
.
Miletić Mary W Heat shock protein gp96 and CD4+ and CD8+ T lymphocytes expression as prognostic factors in various molecular types of invasive breast carcinoma. Neoplasma 2020
.
Artice
. Forthcoming.
8.
Momenimovahed
Z
,
Salehiniya
H
.
Epidemiological characteristics of and risk factors for breast cancer in the world
.
Breast Cancer (Dove Med Press)
.
2019
Apr
;
11
:
151
64
.
[PubMed]
1179-1314
9.
Hanahan
D
,
Weinberg
RA
.
Hallmarks of cancer: the next generation
.
Cell
.
2011
Mar
;
144
(
5
):
646
74
.
[PubMed]
0092-8674
10.
Hanahan
D
,
Coussens
LM
.
Accessories to the crime: functions of cells recruited to the tumor microenvironment
.
Cancer Cell
.
2012
Mar
;
21
(
3
):
309
22
.
[PubMed]
1535-6108
11.
Linde
N
,
Casanova-Acebes
M
,
Sosa
MS
,
Mortha
A
,
Rahman
A
,
Farias
E
, et al.
Macrophages orchestrate breast cancer early dissemination and metastasis
.
Nat Commun
.
2018
Jan
;
9
(
1
):
21
.
[PubMed]
2041-1723
12.
Bense
RD
,
Sotiriou
C
,
Piccart-Gebhart
MJ
,
Haanen
JB
,
van Vugt
MA
,
de Vries
EG
, et al.
Relevance of tumor-infiltrating immune cell composition and functionality for disease outcome in breast cancer
.
J Natl Cancer Inst
.
2016
Oct
;
109
(
1
):
1
9
.
[PubMed]
1460-2105
13.
Franklin
RA
,
Liao
W
,
Sarkar
A
,
Kim
MV
,
Bivona
MR
,
Liu
K
, et al.
The cellular and molecular origin of tumor-associated macrophages
.
Science
.
2014
May
;
344
(
6186
):
921
5
.
[PubMed]
0036-8075
14.
Mantovani
A
,
Marchesi
F
,
Malesci
A
,
Laghi
L
,
Allavena
P
.
Tumour-associated macrophages as treatment targets in oncology
.
Nat Rev Clin Oncol
.
2017
Jul
;
14
(
7
):
399
416
.
[PubMed]
1759-4774
15.
Martinez
FO
,
Gordon
S
,
Locati
M
,
Mantovani
A
.
Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression
.
J Immunol
.
2006
Nov
;
177
(
10
):
7303
11
.
[PubMed]
0022-1767
16.
Mosser
DM
,
Edwards
JP
.
Exploring the full spectrum of macrophage activation
.
Nat Rev Immunol
.
2008
Dec
;
8
(
12
):
958
69
.
[PubMed]
1474-1733
17.
Mantovani
A
,
Sozzani
S
,
Locati
M
,
Allavena
P
,
Sica
A
.
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes
.
Trends Immunol
.
2002
Nov
;
23
(
11
):
549
55
.
[PubMed]
1471-4906
18.
Biswas
SK
,
Mantovani
A
.
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
.
Nat Immunol
.
2010
Oct
;
11
(
10
):
889
96
.
[PubMed]
1529-2908
19.
Kitamura
T
,
Qian
BZ
,
Soong
D
,
Cassetta
L
,
Noy
R
,
Sugano
G
, et al.
CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages
.
J Exp Med
.
2015
Jun
;
212
(
7
):
1043
59
.
[PubMed]
0022-1007
20.
Bonapace
L
,
Coissieux
MM
,
Wyckoff
J
,
Mertz
KD
,
Varga
Z
,
Junt
T
, et al.
Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis
.
Nature
.
2014
Nov
;
515
(
7525
):
130
3
.
[PubMed]
0028-0836
21.
Medrek
C
,
Pontén
F
,
Jirström
K
,
Leandersson
K
.
The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients
.
BMC Cancer
.
2012
Jul
;
12
(
1
):
306
.
[PubMed]
1471-2407
22.
Tymoszuk
P
,
Evens
H
,
Marzola
V
,
Wachowicz
K
,
Wasmer
MH
,
Datta
S
, et al.
In situ proliferation contributes to accumulation of tumor-associated macrophages in spontaneous mammary tumors
.
Eur J Immunol
.
2014
Aug
;
44
(
8
):
2247
62
.
[PubMed]
0014-2980
23.
DeNardo
DG
,
Brennan
DJ
,
Rexhepaj
E
,
Ruffell
B
,
Shiao
SL
,
Madden
SF
, et al.
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy
.
Cancer Discov
.
2011
Jun
;
1
(
1
):
54
67
.
[PubMed]
2159-8274
24.
Georgoudaki
AM
,
Prokopec
KE
,
Boura
VF
,
Hellqvist
E
,
Sohn
S
,
Östling
J
, et al.
Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis
.
Cell Rep
.
2016
May
;
15
(
9
):
2000
11
.
[PubMed]
2639-1856
25.
Gnant
M
,
Mlineritsch
B
,
Stoeger
H
,
Luschin-Ebengreuth
G
,
Heck
D
,
Menzel
C
, et al.;
Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria
.
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial
.
Lancet Oncol
.
2011
Jul
;
12
(
7
):
631
41
.
[PubMed]
1470-2045
26.
Lim
SY
,
Yuzhalin
AE
,
Gordon-Weeks
AN
,
Muschel
RJ
.
Targeting the CCL2-CCR2 signaling axis in cancer metastasis
.
Oncotarget
.
2016
May
;
7
(
19
):
28697
710
.
[PubMed]
1949-2553
27.
Liang
Z
,
Zhan
W
,
Zhu
A
,
Yoon
Y
,
Lin
S
,
Sasaki
M
, et al.
Development of a unique small molecule modulator of CXCR4
.
PLoS One
.
2012
;
7
(
4
):
e34038
.
[PubMed]
1932-6203
28.
Laskarin
G
,
Redzovic
A
,
Vukelic
P
,
Veljkovic
D
,
Gulic
T
,
Haller
H
, et al.
Phenotype of NK cells and cytotoxic/apoptotic mediators expression in ectopic pregnancy
.
Am J Reprod Immunol
.
2010
Nov
;
64
(
5
):
347
58
.
[PubMed]
1046-7408
29.
Kamiya
T
,
Seow
SV
,
Wong
D
,
Robinson
M
,
Campana
D
.
Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells
.
J Clin Invest
.
2019
Mar
;
129
(
5
):
2094
106
.
[PubMed]
0021-9738
30.
Gulic
T
,
Laskarin
G
,
Dominovic
M
,
Glavan Gacanin
L
,
Babarović
E
,
Rubesa
Z
, et al.
Granulysin-mediated apoptosis of trophoblasts in blighted ovum and missed abortion
.
Am J Reprod Immunol
.
2018
Sep
;
80
(
3
):
e12978
.
[PubMed]
1046-7408
31.
Silva
GB
,
Silva
TG
,
Duarte
RA
,
Neto
NL
,
Carrara
HH
,
Donadi
EA
, et al.
Expression of the Classical and Nonclassical HLA Molecules in Breast Cancer.
International Journal of Breast Cancer Volume
2013
, Article ID 250435, 9 pages.
32.
Mamessier
E
,
Sylvain
A
,
Thibult
ML
,
Houvenaeghel
G
,
Jacquemier
J
,
Castellano
R
, et al.
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity
.
J Clin Invest
.
2011
Sep
;
121
(
9
):
3609
22
.
[PubMed]
0021-9738
33.
Tu
MM
,
Rahim
MM
,
Sayed
C
,
Mahmoud
AB
,
Makrigiannis
AP
.
Immunosurveillance and Immunoediting of Breast Cancer via Class I MHC Receptors
.
Cancer Immunol Res
.
2017
Nov
;
5
(
11
):
1016
28
.
[PubMed]
2326-6066
34.
Muraro
E
,
Martorelli
D
,
Turchet
E
,
Miolo
G
,
Scalone
S
,
Comaro
E
, et al.
A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies
.
Breast Cancer Res
.
2011
;
13
(
6
):
R117
.
[PubMed]
1465-5411
35.
Tallerico
R
,
Conti
L
,
Lanzardo
S
,
Sottile
R
,
Garofalo
C
,
Wagner
AK
, et al.
NK cells control breast cancer and related cancer stem cell hematological spread.
ONCOIMMUNOLOGY
2017
;. 6(3) e1284718 (11)
36.
Oyer
JL
,
Gitto
SB
,
Altomare
DA
and
Copik
AJ
. PD-L1 blockade enhances anti-tumor efficacy of NK cells. OncoImmunology, 7:11, e1509819.
37.
Garner
WL
,
Minton
JP
,
James
AG
,
Hoffmann
CC
.
Human breast cancer and impaired NK cell function
.
J Surg Oncol
.
1983
Sep
;
24
(
1
):
64
6
.
[PubMed]
0022-4790
38.
Campbell
MJ
,
Baehner
F
,
O’Meara
T
,
Ojukwu
E
,
Han
B
,
Mukhtar
R
, et al.
Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast
.
Breast Cancer Res Treat
.
2017
Jan
;
161
(
1
):
17
28
.
[PubMed]
0167-6806
39.
Mattiola
I
,
Tomay
F
,
De Pizzol
M
,
Silva-Gomes
R
,
Savino
B
,
Gulic
T
, et al.
The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cell-mediated resistance to metastasis
.
Nat Immunol
.
2019
Aug
;
20
(
8
):
1012
22
.
[PubMed]
1529-2908
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.